Since its discovery in 1979, many studies have reported that the p53 tumour suppressor protein could be expressed in the form of products smaller than those predicted by the full-length amino-acid sequence. These products differ from full-length p53 in their N-or C-terminal regions, but generally conserve the central, DNA-binding domain. They appear to be expressed at rather low levels and to be restricted to particular cell types and/or physiological circumstances, suggesting that they play very narrow and specific roles. Several mechanisms have been proposed to explain their timely occurrence, including alternative splicing, internal initiation of translation or proteolytic cleavage. A precise assessment of the various 'p53 isoforms' reveals striking similarities with several isoforms of the p53 homologous proteins p63 or p73, suggesting that regulated production of specific, N-or C-terminal variants may be a 'trademark' of all family members. In this review, we summarize the published evidence on the structure, mode of production, expression and function of the p53 isoforms, and discuss their properties in the light of recent data on the structure and function of p63/p73 isoforms.
Introduction
Since its discovery in 1979, the history of the p53 protein has been full of twists and turns, and one of the most spectacular is the recent identification of several genes encoding p53 relatives, after many years of the belief that p53 was an orphan tumour suppressor. The discovery of p63 and p73, the two other members of the p53 family, dates from 1997 (Kaghad et al., 1997; Yang et al., 1998) . These two new proteins have strong homologies with p53, not so much in terms of primary sequence, but in terms of overall domain structure and conformation. However, in contrast with p53, it rapidly emerged that the new cousins had complex mechanisms of regulation, based on alternative splicing and on the use of several promoters. Consequently, they are expressed as multiple isoforms, truncated at the N-or C-terminus, that all contain the same, central DNAbinding domain. In p53, these two extreme regions carry essential biological functions, even if the function specificity (regulation of transcription) is conferred by DNA-binding domain (May and May, 1999) .
The N-terminal region contains the transactivation domain, which is divided into two subdomains with complementary functions (Candau et al., 1997; Venot et al., 1999) . While the main domain (1-41) provides the generic transactivation functions, the second one (42-63) may play a role in the selection of specific transactivation targets. The first domain also contains the binding site for Mdm2 (19) (20) (21) (22) (23) (24) (25) (26) , the main regulator of p53 protein stability (Momand et al., 2000) . These two domains are followed by a proline-rich region (PXXP) (64-92), with complex roles as a protein-binding site and as a specific regulator of apoptosis (Venot et al., 1998) .
The C-terminus includes several domains involved in oligomerization and in the regulation of the DNA-binding activity . Moreover, C-terminus itself possesses a nonspecific DNA-binding activity, which seems to be implicated in p53-mediated repair of damaged DNA and in DNA and RNA reannealing . The mechanism by which the C-terminus could regulate the specific DNAbinding of p53 is still controversial. Initially, the extreme C-terminus has been reported to exert repressive effects on DNA-binding activity through the control of p53 conformation (Hupp et al., 1992) . On the other hand, the extreme C-terminus also mediates nonspecific interactions with DNA that may interfere with sequence-specific DNA-binding through the central domain (Bayle et al., 1995; Anderson et al., 1997) . Recent NMR analyses of p53 proteins that either contain or lack the C-terminus have ruled out a major effect on the overall conformation of the protein (Ayed et al., 2001) . However, the exact role of the C-terminus in p53 regulation is still poorly understood (Ahn and Prives, 2001) .
Over the years, a number of size variants of the p53 protein have been described in the literature. The concept that p53 is not present and functional as a single form was initially described by Rotter and co-workers, who reported the existence in mouse cells of a size variant generated by alternative spicing, ASp53 (alternatively spliced p53) (Wolf et al., 1985) . However, this variant has never been found in human cells, suggesting that this mode of regulation may be speciesspecific, and of little relevance for the generic functions of p53. Since 1985, a number of publications have accumulated showing the existence of shorter forms of p53 arising through various mechanisms, such as alternative splicing, autodegradation, proteolytic cleavage and internal translation initiation. Their functions and regulation are poorly understood and they have often been dismissed as artefacts or marginal events. Close examination, however, indicates that they share many structural similarities with the size variants of p63 and p73: they conserve an intact DNA-binding domain and show variations in their N-and C-terminal regions (Melino et al., 2002) .
Recent data provide evidence for the existence of p53 isoforms in human normal and cancerous cells, which may play a role in the regulation of the suppressive activity of wild-type p53. However, the potential role of the various isoforms has not been investigated in detail, and the results available remain controversial. The activities reported for these variants either reinforce the suppressive effect of wild-type p53, or on the contrary, counteract the transactivation and suppressive activities through dominant-negative effect. The concept that the same gene can be expressed as several isoforms, with different functions (i.e. activator or repressor), has already been established for a number of genes such as erbAa, fosB or CREM (Foulkes and Sassone-Corsi, 1992) .
In this review, we describe the p53 isoforms reported in the literature, discuss the putative functions of the resulting proteins and compare them with those of p63 and p73 isoforms.
Structure of p53 isoforms

Alternatively spliced variants
In 1986, Rotter and co-workers have reported the existence of a p53 isoform with a different C-terminus than wild-type. This isoform was first identified in 1985 as a possible mutant occurring in mouse fibroblasts transformed by methylcholanthrene (Wolf et al., 1985) . Sequencing revealed that the isoform was an alternatively spliced product that uses a cryptic acceptor site in intron 10, located 96 bp ahead of the normal acceptor site of exon 11 (Arai et al., 1986) . The alternative splicing results in a protein that lacks the last 26 amino acids, replaced by 17 new residues (Figure 1 ). The alternatively spliced RNA represents about 25-30% of the major p53 RNA species, in both normal and cancerous murine cells and tissues (Han and KuleszMartin, 1992 Laverdiere et al., 2000) . Laverdiere et al. observed that the human Panc cell line could produce detectable levels of ASp53 from a murine expression vector, containing sequences from exon 10 to 11, indicating that this human cell line has all the necessary splicing factors to generate ASp53 mRNA from a heterologous murine p53 pre-mRNA. In the reverse experiment, however, they were unable to detect any human ASp53 mRNA after transfection of a human p53 expression vector into mouse or rat cells. Based on sequence data, the human equivalent of ASp53 splice site appears to be intrinsically weak or nonfunctional. The presence of a strong negative regulatory element in the human p53 splicing unit inhibiting the production of ASp53 mRNA in normal conditions cannot be ruled out. The absence of human ASp53 could also be explained by the difference between murine and human TP53 sequences. PCR amplification between exons 10 and 11 gave a product of different lengths in different species (human: 1105 bp; gorilla: 1150 bp; mouse: 778 bp; rat: 884 bp) (Laverdiere et al., 2000) . This difference is due to the presence of an Alu element in the intron 10 of primate genes. The homology between the intron 10 of mouse and rat TP53 is 78%, compared to only 42% between human and mouse or human and rat, excluding the Alu element. Flaman et al. (1996) described the existence of another alternatively spliced species in normal human cells (I9 þ ). This isoform was identified using FASAY, a functional yeast-based assay for the detection of forms of p53 unable to bind DNA. Expression of cDNA from normal peripheral blood lymphocytes in this assay constantly generates a recurrent background of 5-10% of yeast colonies with defective p53 DNA-binding activity. Cloning and sequencing of the p53 cDNA from those colonies revealed the presence of an alternative spliced form, containing an additional 133 bp exon derived from intron 9. This splice variant encodes a protein of 341 amino acids including 10 new residues derived from the additional exon. Semiquantitative RT-PCR experiments showed that I9 þ mRNA is present in most normal cells and tissues, the highest levels being detectable in peripheral blood lymphocytes, where the majority of cells are quiescent and the amount of regularly spliced p53 mRNA (RSp53) is low (wild-type p53 is referred to as RSp53 (regularly spliced) in the text). There are no data on the pattern of expression of the I9 þ protein in normal cells.
A third alternatively spliced variant was described by Matlashewski et al. (1987) . This splicing occurs at the 5 0 end of p53 RNA and affects the N-terminus of the protein (cDNA type II) (Matlashewski et al., 1987) . It is detectable in normal and transformed human cells. How this splice variant arises is not understood, as the 5 0 end of the RNA has not been properly described. Therefore, the possibility remains that this transcript may be generated by initiation of transcription at a cryptic p53 protein variants S Courtois et al promoter in exon 2 or intron 2. The primary structure of the corresponding protein has not been identified. The predicted change in exon 2 removes the normal initiation codon. The resulting protein theoretically possesses 16 new amino acids instead of the first 25 normal amino acids of the wild-type protein but does not contain any ATG. However, the conservation of the normal splicing pattern for exons 4-11 suggests that type II mRNA encodes a 47 kDa protein initiated at an ATG located at codon 40 in exon 4.
Internal initiation of translation
The production of N-terminally deleted isoforms by internal initiation of translation is a common feature in several transcription factors including VHL, WT1 and human estrogen receptor (Barraille et al., 1999; Blankenship et al., 1999; Scharnhorst et al., 1999) . Two identical, N-terminally truncated p53 forms have been described in the literature, termed p53/47 and DNp53 (Courtois et al., 2002; Yin et al., 2002) . The human p53 coding sequence contains several, in-frame ATG that are potential translation initiation sites. We have recently shown that an ATG located at codon 40 could be used as an alternative initiation site. In the breast cancer cell line 21PT, in which an insertion mutation at codon 33 prevents the synthesis of full-length p53 protein, the use of codon 40 for initiation results in the production of a 47 kDa protein. The protein lacks the first 39 residues (corresponding to the transactivation domain) but contains intact DNA-binding and oligomerization domains (DNp53). Site-directed mutagenesis experiments on human p53 cDNA have confirmed that this second ATG can be used as an initiation codon even in the presence of a functional, first ATG. Indeed, a form of p53 compatible with DNp53 is detectable in most cell , a mouse-specific isoform. The intron/exon structure of the gene is presented at the top, and structural domains of the various isoforms are depicted below. Exons are coloured according to the functional domain of the protein to which they contribute. Yellow: N-terminal domain; blue: DNA-binding domain; green: C-terminal domain; grey: noncoding exons of RSp53 and p53II (Matlashewski et al., 1987) ; red: alternative exon identified in I9 þ p53 (Flaman et al., 1996) ; purple: alternative exon incorporated in ASp53 (Wolf et al., 1985) . The major ATG and STOP position are indicated in black. A second, alternative ATG at position 40 in DNp53 (Courtois et al., 2002) A calpain-independent mechanism, which is based on an interaction with DNA, has been proposed by Milner and co-workers (Molinari et al., 1996; Okorokov et al., 1997) . Their hypothesis is that the pattern of truncation of p53 varies, depending on the type (single or double strand) and integrity (damaged or not) of bound DNA. Interaction with damaged, double-strand DNA generates p35 (core domain) and p40 kDa (DN) proteins (Molinari et al., 1996) , whereas interaction with single-strand DNA induces p50(DC) and p40(DC) proteins (Okorokov et al., 1997) . The p35 isoform was described to exert a protease activity on its own, inducing the cleavage, between residues 23 and 24, of wild-type p53 to generate p50(DN23) (Okorokov et al., 1997) . Such cleavage could only be explained by unusually specific protease(s) or by autoproteolysis.
Recently, a p40 isoform of p53 has been observed after treatment of human hepatoma and colorectal cancer cell lines with either doxorubicin, which induces DNA strand breaks, or octreotide, a somatostatin analogue which does not induce detectable DNA damage (Sadji-Ouatas et al., 2002) . This p53 variant does not react with PAb421 (epitope: 372-378) and is therefore interpreted as resulting from C-terminal truncation. However, how this variant is produced is not known. Since there is no evidence for the presence of an alternative p53 transcript in cells treated by doxorubicin or by octreotide, the authors have suggested that p40 may be generated by proteoloysis. More experiments are needed to explain the origin and function of this isoform.
Structural homology between the p53 variants and the other members of the family
The p53 isoforms described above show variations in their N-and C-terminus, but retain an intact, central region that corresponds to the DNA-binding domain. In this respect, they resemble the other members of the family, p63 and p73 (Kaghad et al., 1997; Schmale and Bamberger, 1997; Osada et al., 1998; Senoo et al., 1998; Trink et al., 1998; Yang et al., 1998) . These two proteins are expressed as multiple isoforms, which all conserve the DNA-binding domain but differ by their N-or Cterminal region. C-terminal variants are generated by alternative splicing between exons 10 and 15. Six different forms have been identified for p73 (a, b, g, d, e and z) (De Laurenzi et al., 1998; De Laurenzi et al., 1999; Ueda et al., 1999) and three for p63 (a, b and g) (Yang et al., 1998) . N-terminal variants show differences in the transactivation domain. They are generated by several mechanisms, including alternative splicing and the use of an internal promoter in intron 3 (P2). These N-truncated forms lack the main transactivation domain and are termed 'D' forms, as opposed to 'TA', transactivation-competent forms. However, D forms may retain some transcriptional capacity through hypothetical, secondary domains located elsewhere in the protein (Dohn et al., 2001; Ghioni et al., 2002) . Several types of D forms are distinguished according to their exact divergence with TA counterparts. For p73, D2, D3 and D2/3 arise by alternative splicing of, respectively, exons 2, 3 or both. DNp73 lacks exons 1, 2 and 3 and is generated from a cryptic promoter in intron 3 (P2), resulting in the use of an initiation codon located in an alternative exon 3 0 (Melino et al., 2002) . DN 0 p73 corresponds to a protein identical to DNp73, but translated from an mRNA initiated at the first promoter and incorporating the 3 0 portion of the alternative exon 3 0 . For p63, only DN variants initiated at the P2 promoter have been identified so far (Yang et al., 2002) . However, a different, transcriptioncompetent N-terminal variant, TA * p63, has been identified in the mouse. This variant contains 39 additional amino acids resulting from the use of an inframe AUG located upstream of the major initiation site. This codon is not conserved in human TP63.
By analogy with p73 and p63 isoforms, we suggest to identify the p53 variants described above using the same nomenclature system: the wild-type RSp53 protein is equivalent to a TAp53a form, since it contains the entire transactivation domain and the longest identified Cterminal domain, including a negative regulatory domain located in the extreme C-terminus, a feature also present in TAp63a. Moreover, ASp53 may be identified as TA * p53b, the asterik indicating that similar to TA * p63, it has so far only been identified in the mouse.
The N-terminally truncated p53 isoforms are structurally and biochemically equivalent to DN p63/p73 variants and may be termed DNp53. The only form identified so far would thus correspond to DNp53a. This form is not produced by alternative splicing, but by p53 protein variants S Courtois et al internal initiation of translation. In this respect, it is more similar to the DN 0 variant of p73, which is transcribed from the main P1 promoter but initiated from an alternative ATG in exon 3 0 . It remains to be determined whether the p53 variant identified by the Matlashewski et al. (1987) is a D2p53 form (generated by alternative splicing) or a DNp53 form (generated from a cryptic promoter in exon/intron 2).
Functions of p53 isoforms
N-terminus variants
There is only limited data on the function of N-terminus variants of p53. Studies by Pariat et al. (1997) and Kubbutat and Vousden (1997) on the calpain-dependent and -independent proteolytic p53 cleavage do not address the function of these products. Studies by Brain and Jenkins (1994) using recombinant p53 have shown that N-truncated proteins have an enhanced DNAstrand-reassociation activity through a domain located in the C-terminus. Milner and co-workers have proposed this effect as a possible mechanism of action for the cleavage products they have identified (Molinari et al., 1996; Okorokov et al., 1997) . However, this hypothesis has not been substantiated by functional studies.
More extensive functional evidence is available on the role of the DNp53 isoform. The study by Yin et al. (2002) concludes that the ratio between RSp53 and DNp53 is controlled by Mdm2 through a dual mechanism, involving enhanced translation of both proteins and preferential degradation of RSp53 (Yin et al., 2002) . These authors have also shown that cotransfection of DNp53 in excess to RSp53 in the p53-null lung cancer cell line H1299 represses the transcription of p21WAF-1 and enhances the expression of BAX. Furthermore, overexpression of DNp53 induced apoptosis with a similar efficiency as RSp53. It is however unclear how DNp53, which lacks the transactivation domain, may differentially regulate transcription. On the other hand, the study by Courtois et al. (2002) has shown that DNp53, when cotransfected in excess to RSp53 in another p53-null lung cancer cell line, H358, exerts a dominant-negative effect and inactivates the ability of RSp53 to suppress colony formation. This study did not report a pro-apoptotic effect. Both interpretations are supported by independent data. Zhu et al. (1998) have described an apoptotic activity induced by the expression of an artificial, N-terminally truncated p53 (D1-42). In contrast, studies by Unger et al. (1992) have shown that a protein lacking the first 42 residues had a dominant-negative activity on transcription by RSp53. Surprisingly, this effect was observed in H1299 cells, the same cells as used by Yin et al. (2002) . The reasons for this discrepancy are unclear.
The intracellular levels of DNp53 proteins do not follow the same variations as those of RSp53. Owing to the absence of the Mdm2 binding domain, DNp53 does not accumulate in response to genotoxic stress. Using serum-starved normal fibroblasts arrested in G0/G1, we have observed opposite changes in the respective levels of RSp53 and DNp53 that immediately precede the entry into S phase induced by restimulation with serum. These changes resulted in DNp53 becoming the major p53 isoform at the time of entry into the S phase. We have therefore suggested that the temporary predominance of DNp53 may help the cells to bypass a normal, RSp53-dependent checkpoint during cell-cycle progression (Courtois et al., 2002) . The functional properties of DNp53 show similarities with the DN isoforms of p63 and p73, since these isoforms have been described as dominant-negative regulators of their TA counterparts. Inhibition of TAp73 function by DNp73 is mediated by protein interactions (Ishimoto et al., 2002; Stiewe et al., 2002) and results in protection against apoptosis (Pozniak et al., 2000; Fillippovich et al., 2001; Ishimoto et al., 2002; Stiewe et al., 2002) . As for DNp63, its expression has been mainly described in the basal cell compartment of squamous epithelium, highlighting a possible role as a dominant-negative repressor of differentiation induced by TAp63 isoforms (Yang et al., 1998) .
C-terminus variants
The I9 þ variant described by Flaman et al. (1996) does not bind DNA in vitro and is defective for transcription in mammalian cells. The alternative splicing giving rise to the I9 þ isoform induces the addition of 10 amino acids at the distal junction of exon 9, thus modifying the C-terminal region. The predicted consequence of this modification is the loss of the oligomerization domain, a defect that may explain the loss of DNA-binding activity. However, the functional consequence of this modification remains unclear.
There is more extensive evidence on the functional significance of the mouse-specific ASp53 isoform. A number of in vitro studies have shown that ASp53 exerts a constitutive DNA-binding activity greater than wildtype p53 (Wu et al., 1994; Wolkowicz et al., 1995) . This effect is consistent with the predicted structure of ASp53, which lacks the negative regulatory region located in the extreme C-terminus. With regularly spliced p53 (RSp53), high-affinity binding in vitro requires the neutralization of the negative regulatory region (Halazonetis and Kandil, 1993) , commonly achieved through the binding of the monoclonal antibody PAb421 to a C-terminal epitope (epitope: 370-377). This epitope is deleted in the ASp53 form, explaining its high, constitutive DNA-binding activity. Oligomerization of ASp53 with RSp53 decreases the constitutive binding activity but restores its inducibility upon PAb421 binding.
Functional data point to a possible physiological role of ASp53 in the differentiation of keratinocytes and in the response to serum starvation. Both ASp53 and RSp53 mRNAs are expressed in normal cells and are responsive to EGF stimulation and to serum starvation (Han and Kulesz-Martin, 1992) . During keratinocyte differentiation, RSp53 is preferentially expressed in p53 protein variants S Courtois et al basal cells, whereas ASp53 is the predominant, if not the only, form in terminally differentiated cells. Moreover, the two proteins differ by the cellular localization, nuclear for RSp53 and cytoplasmic for ASp53 (Rehberger et al., 1997) . These results suggest that the two forms may perform a balancing act that controls keratinocyte growth and differentiation. The mechanisms responsible for the differential regulation of ASp53 expression are unknown. A study by Wesierska-Gadek et al. (1999) indicates that poly-ADP ribose polymerase (PARP) selectively destabilizes RSp53 mRNA, but it is not known how this mechanism contributes to the spatiotemporal expression patterns observed in keratinocytes.
There is also good evidence that ASp53 may exert a similar balancing role in cell cycle and in apoptosis. First, Kulesz-Martin et al. (1994) have shown that the ASp53 protein is preferentially expressed in the G2 phase of the cell cycle, compared to RSp53, which is preferentially expressed in G1. Second, ASp53 can induce an attenuated form of apoptosis characterized by a late onset (24-36 h) when compared with RSp53 (12-18 h) . The pro-apoptotic effects of the two forms are not additive, and increasing the level of ASp53 reduces apoptosis induced by RSp53. Overall, these results are consistent with the notion that p53 induces apoptosis through several mechanisms, some of them dependent upon a domain located in the C-terminus and altered in ASp53. Interestingly, ASp53 does not carry the in vitro strand-reassociation activity of RSp53, which has been mapped to the extreme Cterminus of the protein. However, the relevance of this activity for p53-dependent apoptosis remains to be established.
As discussed above for N-terminal p53 variants, the functional properties of C-terminal variants also show similarities with the C-terminal isoforms of p63 and p73. A domain that negatively regulates transactivation has been identified in the extreme C-terminus of TAp63a using both reporter gene and colony formation assays (Ozaki et al., 1999) . Negative regulation involves a conformation-dependent interaction between the extreme C-terminus and the N-terminal transcriptional activation domains. This inhibition is somewhat similar to the one proposed for the negative regulation of p53 by its C-terminal domain, although, in the case of p53, the conformation-dependent interaction prevents DNAbinding, rather than transcriptional activation. However, it should be stressed that the C-terminal regions of p63 and p73 contain motifs that have no structural equivalent in p53, such as the SAM (sterile alpha motif) present in the a and z isoforms of p73 and in the a isoform of p63. This protein-protein interaction domain is thought to be involved in the regulation of developmental processes, distinct from those in which p53 may play a role (Chi et al., 1999; Thanos and Bowie, 1999) .
p53 family traits: a global perspective
Until recently, little attention has been paid to the role of p53 isoforms, as they were generally considered to be of marginal importance. However, the recent accumulation of information on the structure and function of p63 and p73 isoforms calls for a reassessment of these p53 isoforms. Indeed, the data summarized here indicate that these isoforms show structural and functional similarities to those of p63 and p73. These features may represent a 'trademark' of the p53 protein family, characterized by an invariant DNA-binding domain, flanked by N-and C-terminal domains of variable size, determining the transcriptional effect and the degree of activation of the protein. Nevertheless, the mechanisms generating p53 and p63/p73 isoforms are quite different, probably resulting from different biological functions rather than phylogenetic divergence. Whereas p63 and p73 variants mainly result from a classical alternative splicing, p53 isoforms can also be generated by various mechanisms directly targeting the protein. This regulation at the protein level could result from the involvement of p53 in stress response. Indeed, this may constitute a rapid process to switch between p53 forms with repressive or permissive activity on cell cycle. Another important feature of the p53 family is the existence of conformational interactions between the three main domains. It is thus quite remarkable that the preferential target for mutations in p53 in human cancers is the invariant, DNA-binding domain, suggesting that alterations in the N-or C-terminus regions modulate the properties of the isoforms generated, rather than totally abrogate their functions. Figure 2 shows a general model, applicable to all p53 family members, of the functional crosstalks between full-length and variant forms. The basic, suppressive activities of the full-length isoform in the control of cell cycle arrest and in apoptosis can be modulated, either positively by C-terminal isoforms (constitutive activation) or negatively by N-terminal isoforms (dominant-negative effect). Depending on the differential regulation of these isoforms, these proteins may thus play a number of complex roles in the control of growth, differentiation and development. In particular, the generation of a gradient of expression of different isoforms within a given tissue may represent an important signal for the spatial and temporal regulation of differentiation, as illustrated by the expression of p63 isoforms in squamous epithelia.
The biological functions of p53 isoforms remain to be elucidated. In contrast to full-length p53, there is no evidence that any of the N-or C-terminal variants accumulate in response to genotoxic stress. Therefore, their functions are likely to be relevant to the involvement of p53 in controlling normal, physiological processes. In cells exposed to stress, the accumulated full-length form is by far the dominant isoform, and it is unlikely that the low levels of p53 variants can have a significant biological effect. However, in non-stressed cells, the levels of p53 variants may match and sometimes surpass those of full-length p53, thus exerting important regulatory effects. Therefore, future work should concentrate on the elucidation of the mechanism that selectively regulates the expression of each isoform (alternative splicing, use of alternative p53 protein variants S Courtois et al promoter and/or initiation codon, differential protein stabilization). Another, unresolved question relates to the role of p53 variants in tumorigenesis. There is evidence that, in many tumour cell lines, various small forms of p53 are present at detectable levels. However, the exact identity of these forms is not known. Overexpression of a DN isoform may potentially inhibit wild-type p53 function in tumour cells that conserve wild-type alleles. Moreover, the effect of a mutation in the DNA-binding domain on the activity of the N-and C-terminal isoforms is still a matter of speculation. Further studies are needed to investigate the expression of specific p53 isoforms in primary tumours and to analyse the interactions between the various family members during tumour progression.
